非ホジキンリンパ腫患者に対するCHOP療法に伴う発熱性好中球減少症の1次予防におけるペグフィルグラスチムの費用対効果
「緒言」非ホジキンリンパ腫(non-Hodgkin lymphoma:NHL)は悪性リンパ腫の一種であり, 化学療法により治癒を含む十分な効果が期待できる. 一方, 治療強度を減弱することが治療成績を低下させると報告されており, 治療強度を維持することが重要である. 本邦ではびまん性大細胞型B細胞リンパ腫(diffuse large B-cell lymphoma: DLBCL)が全NHLの3割強を占め, 主な治療としてシクロホスファミド, アドリアマイシン, ビンクリスチン, プレドニゾロン, リツキシマブを組み合わせたR-CHOP療法が行われる. R-CHOP療法は重篤な骨髄抑制を引き起こ...
Saved in:
| Published in | 医療薬学 Vol. 44; no. 9; pp. 441 - 448 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人日本医療薬学会
10.09.2018
日本医療薬学会 |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | 「緒言」非ホジキンリンパ腫(non-Hodgkin lymphoma:NHL)は悪性リンパ腫の一種であり, 化学療法により治癒を含む十分な効果が期待できる. 一方, 治療強度を減弱することが治療成績を低下させると報告されており, 治療強度を維持することが重要である. 本邦ではびまん性大細胞型B細胞リンパ腫(diffuse large B-cell lymphoma: DLBCL)が全NHLの3割強を占め, 主な治療としてシクロホスファミド, アドリアマイシン, ビンクリスチン, プレドニゾロン, リツキシマブを組み合わせたR-CHOP療法が行われる. R-CHOP療法は重篤な骨髄抑制を引き起こすことが知られ, 欧米では17～50%もの高頻度で発熱性好中球減少症(febrile neutropenia: FN)が出現すると報告されている. FNは重篤な感染症に移行し死に至る可能性があるため, その副作用マネジメントは極めて重要である. |
|---|---|
| AbstractList | 「緒言」非ホジキンリンパ腫(non-Hodgkin lymphoma:NHL)は悪性リンパ腫の一種であり, 化学療法により治癒を含む十分な効果が期待できる. 一方, 治療強度を減弱することが治療成績を低下させると報告されており, 治療強度を維持することが重要である. 本邦ではびまん性大細胞型B細胞リンパ腫(diffuse large B-cell lymphoma: DLBCL)が全NHLの3割強を占め, 主な治療としてシクロホスファミド, アドリアマイシン, ビンクリスチン, プレドニゾロン, リツキシマブを組み合わせたR-CHOP療法が行われる. R-CHOP療法は重篤な骨髄抑制を引き起こすことが知られ, 欧米では17～50%もの高頻度で発熱性好中球減少症(febrile neutropenia: FN)が出現すると報告されている. FNは重篤な感染症に移行し死に至る可能性があるため, その副作用マネジメントは極めて重要である. |
| Author | 佐久間, 昌基 近藤, 有 間瀬, 広樹 山田, 清文 小山, 佐知子 久田, 達也 佐藤, 由美子 一木, 万奈美 大島, 有美子 牛膓, 沙織 築山, 郁人 板倉, 由縁 宮崎, 雅之 杉本, 智哉 荒川, 裕貴 |
| Author_xml | – sequence: 1 fullname: 杉本, 智哉 organization: 名古屋大学医学部附属病院薬剤部 – sequence: 2 fullname: 近藤, 有 organization: JA愛知厚生連豊田厚生病院薬剤部 – sequence: 3 fullname: 一木, 万奈美 organization: 地域医療機能推進機構中京病院薬剤部 – sequence: 4 fullname: 荒川, 裕貴 organization: トヨタ記念病院薬剤科 – sequence: 5 fullname: 間瀬, 広樹 organization: 金沢医療センター薬剤部 – sequence: 6 fullname: 牛膓, 沙織 organization: 名古屋掖済会病院薬剤部 – sequence: 7 fullname: 佐久間, 昌基 organization: 愛知医科大学病院薬剤部 – sequence: 8 fullname: 小山, 佐知子 organization: 名古屋第一赤十字病院薬剤部 – sequence: 9 fullname: 大島, 有美子 organization: 一宮市立市民病院薬剤局 – sequence: 10 fullname: 宮崎, 雅之 organization: 名古屋大学医学部附属病院薬剤部 – sequence: 11 fullname: 築山, 郁人 organization: 愛知医科大学病院薬剤部 – sequence: 12 fullname: 佐藤, 由美子 organization: 名古屋市立西部医療センター薬剤科 – sequence: 13 fullname: 久田, 達也 organization: トヨタ記念病院薬剤科 – sequence: 14 fullname: 板倉, 由縁 organization: 碧南市民病院薬剤部 – sequence: 15 fullname: 山田, 清文 organization: 名古屋大学医学部附属病院薬剤部 |
| BookMark | eNo1kUtPFEEUhTsGExFZ-jMa69VF104zUSAhgYUm7CrVD6Q7Mz2Tbly4o7sCGtw4CUQHlGjQ-BhRBBcDCn_mznQP_8Ji0OTm3JO6Od9Z1E1rLGkmoWXdxmjK4UzciePWip9NMWYGX7PGsesSGzMhxoynjNuUkaUb1mSWRR5CjkAEO3zc-nDxdg_0LhQ9KA5AH4P-OtL2cL1bFvvDtXXIu4Mf55B3oHhRm11YrDpFebxtXvt_fkG-UXVOq42f5dqnwcezfu-geqnL3u7gsF29egb5d1x-e98_fX7x-sgEIN-EvG0woHegOAS9DcU-6O7If4HiBHQO-p2JDY9-V1ufTe1g86Tce3PLur6s6lk4-W9PWI8e3H9Ym7XnF2bmavfm7ZhiguxABK5QIeaKOAxTTzAmMGchwj5XHiLTNHB96rsUoWXiTTMn4Jy4IuRECJ9xSiesmStuIwwiX9WbST1KQhk3n6SJ6ZWB57RWVNqQBGFXIsQYEmZhadxIXIqNQ44h3b0ixdmqehzKVho1VPpUqnQ18usGOfotyZgUl3IZ_3_yTYOMFf0LR_PHgQ |
| ContentType | Journal Article |
| Copyright | 2018 日本医療薬学会 |
| Copyright_xml | – notice: 2018 日本医療薬学会 |
| CorporateAuthor | 名古屋大学医学部附属病院薬剤部 トヨタ記念病院薬剤科 愛知医科大学病院薬剤部 名古屋第一赤十字病院薬剤部 金沢医療センター薬剤部 名城大学薬学部 名古屋市立西部医療センター薬剤科 愛知県病院薬剤師会がん部会 碧南市民病院薬剤部 名古屋掖済会病院薬剤部 地域医療機能推進機構中京病院薬剤部 一宮市立市民病院薬剤局 JA愛知厚生連豊田厚生病院薬剤部 |
| CorporateAuthor_xml | – name: JA愛知厚生連豊田厚生病院薬剤部 – name: 地域医療機能推進機構中京病院薬剤部 – name: 金沢医療センター薬剤部 – name: 一宮市立市民病院薬剤局 – name: 名古屋大学医学部附属病院薬剤部 – name: 名古屋掖済会病院薬剤部 – name: 愛知医科大学病院薬剤部 – name: 名古屋市立西部医療センター薬剤科 – name: 名城大学薬学部 – name: 碧南市民病院薬剤部 – name: 名古屋第一赤十字病院薬剤部 – name: トヨタ記念病院薬剤科 – name: 愛知県病院薬剤師会がん部会 |
| DOI | 10.5649/jjphcs.44.441 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1882-1499 |
| EndPage | 448 |
| ExternalDocumentID | db5pharm_2018_004409_001_0441_04483144105 article_jjphcs_44_9_44_441_article_char_ja |
| GroupedDBID | .LE 5GY ALMA_UNASSIGNED_HOLDINGS KQ8 MOJWN RJT ABJNI |
| ID | FETCH-LOGICAL-j3120-d9d89ae16a25413b9449164e01c6ab0273d8c3c8300f2b745d66289e6299c4633 |
| ISSN | 1346-342X |
| IngestDate | Thu Jul 10 16:10:40 EDT 2025 Wed Apr 05 04:38:24 EDT 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 9 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j3120-d9d89ae16a25413b9449164e01c6ab0273d8c3c8300f2b745d66289e6299c4633 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jjphcs/44/9/44_441/_article/-char/ja |
| PageCount | 8 |
| ParticipantIDs | medicalonline_journals_db5pharm_2018_004409_001_0441_04483144105 jstage_primary_article_jjphcs_44_9_44_441_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 20180910 |
| PublicationDateYYYYMMDD | 2018-09-10 |
| PublicationDate_xml | – month: 09 year: 2018 text: 20180910 day: 10 |
| PublicationDecade | 2010 |
| PublicationTitle | 医療薬学 |
| PublicationTitleAlternate | 医療薬学 |
| PublicationYear | 2018 |
| Publisher | 一般社団法人日本医療薬学会 日本医療薬学会 |
| Publisher_xml | – name: 一般社団法人日本医療薬学会 – name: 日本医療薬学会 |
| References | 9）Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C, Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity, J Clin Oncol, 1998, 16, 2352-2358. 13）Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO, American Society of Clinical Oncology, Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 2015, 33, 3199-3212. 16）Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM, Crawford J, Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review, J Clin Oncol, 2010, 28, 2914-2924. 5）Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, 2002, 346, 235-242. 22）Cutler DM, Rosen AB, Vijan S, The value of medical spending in the United States, 1960-2000, N Engl J Med, 2006, 355, 920-927. 6）Lyman GH, Delgado DJ, Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma, Cancer, 2003, 98, 2402-2409. 25）Lyman G, Lalla A, Barron R, Dubois RW, Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States, Curr Med Res Opon, 2009, 25, 401-411. 14）Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, Mittmann N, Hoch JS, Walker S, Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients, J Natl Cancer Inst, 2013, 105, 1078-1085. 17）Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P, Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy, Eur J Hematol, 2005, 75, 116-123. 7）Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, Lawless G, Kerr R, Caggiano V, Delgado D, Fridman M, Ford J, Carter WB, The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis, Clin Lymphoma, 2001, 2, 47-56. 15）Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A, Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma, Cochrane Database Syst Rev, 2008, 4, CD003189. 24）Potosky AL, Malin JL, Kim B, Chrischilles EA, Makgoeng SB, Howlader N, Weeks JC, Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes, J Natl Cancer Inst, 2011, 103, 979-982. 3）The world health organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists, Pathol Int, 2000, 50, 696-702. 23）Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K, International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?, Health Econ, 2010, 19, 422-437. 19）“診療点数早見表”, 2016年4月版, 医学通信社, 東京, 2016. 26）Danova M, Chiroli S, Rosti G, Doan QV, Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients, Tumori, 2009, 95, 219-226. 2）Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G, Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP, Ann Hematol, 2008, 87, 277-283. 18）“薬価基準点数早見表”, 平成28年4月版, じほう, 東京, 2016. 8）Armitage JO, Potter JF, Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age, J Am Geriatr Soc, 32, 269-273. 12）Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL, Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis, BMC Cancer, 2011, 11, 404 21）Grosse SD, Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold, Expert Rev Pharmacoecon Outcomes Res, 2008, 8, 165-178. 1）国立がん研究センター内科レジデント編, “がん診療レジデントマニュアル第7版”, 医学書院, 東京, 2016, pp12-33. 10）一般社団法人日本癌治療学会編集, “G-CSF適正使用ガイドライン”, 2013年版Ver.2, 金原出版, 東京, 2015, pp37-38, 49-51. 11）Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G, Comparison of pegfilgrastim with filgrastim on febrile neutropenia, Grade Ⅳ neutropenia and bone pain: a meta-analysis of randomized controlled trials, Curr Med Res Opin, 2007, 23, 2283-2295 4）Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma, N Engl J Med, 1993, 328, 1002-1006. 20）日本臨床腫瘍学会編集, “発熱性好中球減少症（FN）診療ガイドライン”, 南江堂, 東京, 2015, pp2-3. |
| References_xml | – reference: 3）The world health organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists, Pathol Int, 2000, 50, 696-702. – reference: 19）“診療点数早見表”, 2016年4月版, 医学通信社, 東京, 2016. – reference: 18）“薬価基準点数早見表”, 平成28年4月版, じほう, 東京, 2016. – reference: 22）Cutler DM, Rosen AB, Vijan S, The value of medical spending in the United States, 1960-2000, N Engl J Med, 2006, 355, 920-927. – reference: 23）Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K, International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?, Health Econ, 2010, 19, 422-437. – reference: 9）Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C, Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity, J Clin Oncol, 1998, 16, 2352-2358. – reference: 4）Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma, N Engl J Med, 1993, 328, 1002-1006. – reference: 10）一般社団法人日本癌治療学会編集, “G-CSF適正使用ガイドライン”, 2013年版Ver.2, 金原出版, 東京, 2015, pp37-38, 49-51. – reference: 13）Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO, American Society of Clinical Oncology, Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 2015, 33, 3199-3212. – reference: 6）Lyman GH, Delgado DJ, Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma, Cancer, 2003, 98, 2402-2409. – reference: 15）Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A, Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma, Cochrane Database Syst Rev, 2008, 4, CD003189. – reference: 24）Potosky AL, Malin JL, Kim B, Chrischilles EA, Makgoeng SB, Howlader N, Weeks JC, Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes, J Natl Cancer Inst, 2011, 103, 979-982. – reference: 17）Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P, Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy, Eur J Hematol, 2005, 75, 116-123. – reference: 20）日本臨床腫瘍学会編集, “発熱性好中球減少症（FN）診療ガイドライン”, 南江堂, 東京, 2015, pp2-3. – reference: 11）Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G, Comparison of pegfilgrastim with filgrastim on febrile neutropenia, Grade Ⅳ neutropenia and bone pain: a meta-analysis of randomized controlled trials, Curr Med Res Opin, 2007, 23, 2283-2295． – reference: 5）Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, 2002, 346, 235-242. – reference: 16）Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM, Crawford J, Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review, J Clin Oncol, 2010, 28, 2914-2924. – reference: 14）Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, Mittmann N, Hoch JS, Walker S, Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients, J Natl Cancer Inst, 2013, 105, 1078-1085. – reference: 26）Danova M, Chiroli S, Rosti G, Doan QV, Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients, Tumori, 2009, 95, 219-226. – reference: 7）Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, Lawless G, Kerr R, Caggiano V, Delgado D, Fridman M, Ford J, Carter WB, The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis, Clin Lymphoma, 2001, 2, 47-56. – reference: 25）Lyman G, Lalla A, Barron R, Dubois RW, Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States, Curr Med Res Opon, 2009, 25, 401-411. – reference: 2）Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G, Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP, Ann Hematol, 2008, 87, 277-283. – reference: 8）Armitage JO, Potter JF, Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age, J Am Geriatr Soc, 32, 269-273. – reference: 21）Grosse SD, Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold, Expert Rev Pharmacoecon Outcomes Res, 2008, 8, 165-178. – reference: 1）国立がん研究センター内科レジデント編, “がん診療レジデントマニュアル第7版”, 医学書院, 東京, 2016, pp12-33. – reference: 12）Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL, Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis, BMC Cancer, 2011, 11, 404． |
| SSID | ssib005902156 ssib003116159 ssib002484604 ssib000871962 ssib023157658 ssj0069027 ssib060196744 |
| Score | 2.1306622 |
| Snippet | 「緒言」非ホジキンリンパ腫(non-Hodgkin lymphoma:NHL)は悪性リンパ腫の一種であり, 化学療法により治癒を含む十分な効果が期待できる. 一方, 治療強度を減弱することが治療成績を低下させると報告されており, 治療強度を維持することが重要である.... |
| SourceID | medicalonline jstage |
| SourceType | Publisher |
| StartPage | 441 |
| SubjectTerms | CHOP cost-effectiveness febrile neutropenia non-Hodgkin lymphoma pegfilgrastim |
| Title | 非ホジキンリンパ腫患者に対するCHOP療法に伴う発熱性好中球減少症の1次予防におけるペグフィルグラスチムの費用対効果 |
| URI | https://www.jstage.jst.go.jp/article/jjphcs/44/9/44_441/_article/-char/ja http://mol.medicalonline.jp/en/journal/download?GoodsID=db5pharm/2018/004409/001&name=0441-0448j |
| Volume | 44 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 医療薬学, 2018/09/10, Vol.44(9), pp.441-448 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1NbxQ3dITSS6Wq6qdKv7QHzIkNM2uPx77VsztR1Io2SEHKbZTZ3QitVIhIONATuyNoRS-NBIKUFhXRqi0BSoFDoB9_xslu-AG99z3bs-tEHAJcRp7n957fh8f2m7HfBMGhhCcJ7XZpHT-r1aFTMHjmIGotiqWC81guUY7nnY99zmdPsE8X4oUDU_95u5bOrhbT7a-eea7kRbwKMPArnpJ9Ds-OmQIAyuBfuIKH4bovH5NMEtkiMiMZJYISmZpCg6TCFVTLVaXUFZTaC5ERyQQRMVFAzg0VNZAQgYgTmSpAmCFp5iBSuiZE2pz9Yo5kCYLgHlgAa-lTMpI2ScocRHCHnCoswG0amYZDohLTTEzSlqESRgFADlFQ5CyMkoAQGrmhCjgkVVuZYaSaREWGXhEhjJEESRueQFYOVakSjVWpTKIqQ4YVJK4sOjZkuhdHVSZJpYOIqKoKxyKiaUGYNDXSM6KEZ9oYpUJyjl6VTT92MLXNitDaGsxh9EUOLaLGr1kNgxYRllMTUeBZMjfW7jGRII-c4INQM64rgEkVG-M3d6EZp4CnHFth0Sy0ch7aPEF1RObzF9BTG8Z3CcpmCAXaE21rbcL8l1CR2THjtiPjsOG1LrAR1NuIai0HHUNRr_sZ_6Ou3GgUT0yxD0O6TiuVN2tTxuuUNRbsosbCMHSE8F_6U71NNeqGNOnN28xmX3NLQGaTv-5dXcScYXLeXm_5ZHtlmrHpMdWuhO1uOMgtXs5YLvECyHlVhScq8x6Eda80ILrF6fmz435UlMC86G12YBAkeG9NaIRhmpd1T-LCfRxVQMQWJ3zy0wQO1eYfU5WVbKph1OboLl1gEd6DkBRzjbz2pf1MbNP1eCvu-TeC112oXFNWmzeDA73Ft4LDczbX_rkjtfnJ0dGVI7XDtblJFv5zbwc_P_3xhi6v68GmHtzV5UNd3jbXtZ0LG8PBrZ3zF3R_Y_uPf3V_XQ--xSFstD4YPrwC0K2_H-n-xdH6k9HFP4fnf93-5Z-tzbuj78rh5vXt-2ujq1_r_r1oeOfm1pNvnl57AAS6f0n314CNLr_Xg_u6vKIHt3S5Ycq_68FjXfZ1-ROQ7Tz4a3T5N2h2-9Lj4Y0f3glOzGTzzdm6-yVNvUejRljvyI6Qi92IL8KsFtFCMgbxNeuGUZsvFpgbrCPatC1oGC41ioTFHc4bQnY5rPrbjFP6bjB16vSp7ntBDUJZCBukKJbamAS1I4G8HXUhogOetEgOBtJ6I1-2eYfy_Xesg8EnuxyYu0lrJe8U8TJ6I8enOMftPKHEfc15iGzgIii-Ygvj91-i-Q-CVyeDxIfB1OqZs92PIHZbLT42Pf1_XEVhww |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E9%9D%9E%E3%83%9B%E3%82%B8%E3%82%AD%E3%83%B3%E3%83%AA%E3%83%B3%E3%83%91%E8%85%AB%E6%82%A3%E8%80%85%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8BCHOP%E7%99%82%E6%B3%95%E3%81%AB%E4%BC%B4%E3%81%86%E7%99%BA%E7%86%B1%E6%80%A7%E5%A5%BD%E4%B8%AD%E7%90%83%E6%B8%9B%E5%B0%91%E7%97%87%E3%81%AE1%E6%AC%A1%E4%BA%88%E9%98%B2%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E3%83%9A%E3%82%B0%E3%83%95%E3%82%A3%E3%83%AB%E3%82%B0%E3%83%A9%E3%82%B9%E3%83%81%E3%83%A0%E3%81%AE%E8%B2%BB%E7%94%A8%E5%AF%BE%E5%8A%B9%E6%9E%9C&rft.jtitle=%E5%8C%BB%E7%99%82%E8%96%AC%E5%AD%A6&rft.au=%E6%9D%89%E6%9C%AC%2C+%E6%99%BA%E5%93%89&rft.au=%E8%BF%91%E8%97%A4%2C+%E6%9C%89&rft.au=%E4%B8%80%E6%9C%A8%2C+%E4%B8%87%E5%A5%88%E7%BE%8E&rft.au=%E8%8D%92%E5%B7%9D%2C+%E8%A3%95%E8%B2%B4&rft.date=2018-09-10&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA%E6%97%A5%E6%9C%AC%E5%8C%BB%E7%99%82%E8%96%AC%E5%AD%A6%E4%BC%9A&rft.issn=1346-342X&rft.eissn=1882-1499&rft.volume=44&rft.issue=9&rft.spage=441&rft.epage=448&rft_id=info:doi/10.5649%2Fjjphcs.44.441&rft.externalDocID=article_jjphcs_44_9_44_441_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1346-342X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1346-342X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1346-342X&client=summon |